Celldex Therapeutics (CLDX) News Today → Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad) Free CLDX Stock Alerts $33.30 -0.32 (-0.95%) (As of 05/31/2024 08:50 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 3 at 8:12 AM | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Celldex Therapeutics (NASDAQ:CLDX)June 2 at 9:01 AM | globenewswire.comCelldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024May 29, 2024 | marketbeat.comMonashee Investment Management LLC Buys New Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Monashee Investment Management LLC bought a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 100,209 shares of the biopharmaceutical company's stock, valued aMay 28, 2024 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Shares Down 5.4% Celldex Therapeutics (NASDAQ:CLDX) Stock Price Down 5.4%May 28, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Acquires 47,844 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Charles Schwab Investment Management Inc. raised its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 13.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 409,391 shares of the biopharmaceutical company's stocMay 20, 2024 | marketbeat.comAssenagon Asset Management S.A. Buys Shares of 90,931 Celldex Therapeutics, Inc. (NASDAQ:CLDX)Assenagon Asset Management S.A. bought a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 90,931 shares of the biopharmaceuticalMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Celldex on Promising Barzolvolimab Trials in Inflammatory DiseasesMay 15, 2024 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Receives "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research report on Wednesday.May 15, 2024 | globenewswire.comCelldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo NodularisMay 10, 2024 | seekingalpha.comCelldex Therapeutics: Rising High, With Room For Further GrowthMay 9, 2024 | marketbeat.comBrokers Issue Forecasts for Celldex Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:CLDX)Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Equities research analysts at Lifesci Capital issued their FY2024 earnings per share (EPS) estimates for Celldex Therapeutics in a research note issued on Tuesday, May 7th. Lifesci Capital analyst S. Slutsky expects that the biopharmaceuticMay 8, 2024 | finance.yahoo.comCelldex Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 7, 2024 | finanznachrichten.deCelldex Therapeutics, Inc.: Celldex Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | markets.businessinsider.comUnveiling 4 Analyst Insights On Celldex TherapeuticsMay 7, 2024 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Earns Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday.May 6, 2024 | investorplace.comCLDX Stock Earnings: Celldex Therapeutics Beats EPS, Misses Revenue for Q1 2024May 6, 2024 | globenewswire.comCelldex Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 19, 2024 | investing.comCelldex completes patient enrollment for Phase 2 urticaria trialApril 17, 2024 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reissued a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday.April 17, 2024 | msn.comCelldex Hails Enrolment News, Shares Poke AheadApril 17, 2024 | finance.yahoo.comCelldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible UrticariaApril 17, 2024 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Trading 2.7% Higher Celldex Therapeutics (NASDAQ:CLDX) Stock Price Up 2.7%April 17, 2024 | globenewswire.comCelldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible UrticariaApril 15, 2024 | marketbeat.comDekaBank Deutsche Girozentrale Acquires Shares of 25,000 Celldex Therapeutics, Inc. (NASDAQ:CLDX)DekaBank Deutsche Girozentrale bought a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 25,000 shares of the biopharmaceuApril 11, 2024 | seekingalpha.comCLDX Celldex Therapeutics, Inc.April 1, 2024 | marketbeat.comShort Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Declines By 8.0%Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) was the target of a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 5,900,000 shares, a drop of 8.0% from the February 29th total of 6,410,000 shares. Based on an average daily trading volume, of 927,100 shares, the short-interest ratio is currently 6.4 days.March 29, 2024 | marketbeat.comSG Americas Securities LLC Sells 31,928 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)SG Americas Securities LLC reduced its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 40.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 46,083 shares of the biopharmaceutical company'March 22, 2024 | marketbeat.comCantor Fitzgerald Reiterates "Overweight" Rating for Celldex Therapeutics (NASDAQ:CLDX)Cantor Fitzgerald reaffirmed an "overweight" rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Friday.March 19, 2024 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Short Interest UpdateCelldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) saw a significant decrease in short interest during the month of February. As of February 29th, there was short interest totalling 6,410,000 shares, a decrease of 7.6% from the February 14th total of 6,940,000 shares. Based on an average daily trading volume, of 863,900 shares, the days-to-cover ratio is presently 7.4 days.March 17, 2024 | finance.yahoo.comCLDX Aug 2024 70.000 callMarch 17, 2024 | marketbeat.comWellington Management Group LLP Buys 300,406 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Wellington Management Group LLP grew its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 5.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,431,833 shares of the biopharmaceutical compaMarch 16, 2024 | finance.yahoo.comCLDX Apr 2024 65.000 callMarch 16, 2024 | finance.yahoo.comCLDX Aug 2024 50.000 callMarch 16, 2024 | finance.yahoo.comCLDX Apr 2024 40.000 callMarch 16, 2024 | finance.yahoo.comCLDX Jan 2025 15.000 putMarch 9, 2024 | marketbeat.comGSA Capital Partners LLP Increases Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX)GSA Capital Partners LLP lifted its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 192.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 44,716 shares of the biopharmaceutical company's stock after purchasingMarch 8, 2024 | globenewswire.comCelldex Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceMarch 6, 2024 | ca.finance.yahoo.comCLDX Jan 2025 30.000 putMarch 6, 2024 | ca.finance.yahoo.comCLDX Jan 2025 70.000 callMarch 6, 2024 | finance.yahoo.comCelldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care ConferenceMarch 5, 2024 | finance.yahoo.comCelldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesMarch 5, 2024 | globenewswire.comCelldex Therapeutics to Present at TD Cowen's 44th Annual Health Care ConferenceMarch 5, 2024 | globenewswire.comCelldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesMarch 4, 2024 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Sets New 52-Week High at $53.18Celldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month High at $53.18March 2, 2024 | investing.comCelldex announces $400.4 million public stock offeringMarch 1, 2024 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Sees Unusually-High Trading VolumeCelldex Therapeutics (NASDAQ:CLDX) Sees Strong Trading VolumeMarch 1, 2024 | marketbeat.comQ1 2024 EPS Estimates for Celldex Therapeutics, Inc. Raised by Leerink Partnrs (NASDAQ:CLDX)Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Research analysts at Leerink Partnrs raised their Q1 2024 earnings per share (EPS) estimates for Celldex Therapeutics in a report issued on Wednesday, February 28th. Leerink Partnrs analyst T. Smith now forecasts that the biopharmaceuticalMarch 1, 2024 | markets.businessinsider.comCelldex Therapeutics Prices Public Offering Of 8.52 Mln Shares At $47.00/shrMarch 1, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Buys 10,818 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Charles Schwab Investment Management Inc. increased its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 3.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 361,547 sharFebruary 29, 2024 | globenewswire.comCelldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Must-See: Elon’s New Invention is Absolutely Insane (Ad)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone. Click here for the full story… CLDX Media Mentions By Week CLDX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLDX News Sentiment▼1.100.77▲Average Medical News Sentiment CLDX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLDX Articles This Week▼62▲CLDX Articles Average Week Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Intellia Therapeutics News Riot Platforms News Neogen News Aspira Women's Health News Lantheus News Exact Sciences News Repligen News Exelixis News Halozyme Therapeutics News Ionis Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLDX) was last updated on 6/3/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldAlert: Your Bank is Dying – Act Now or Lose Everything!Priority GoldNext President (Not Trump. Not Biden.)The Freeport SocietyWrite this ticker symbol down…StocksToTradeTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHistoric Crash Could Wipe Away Your 401k (Govt Debt Explosion)Birch GoldPrepare for a Recession Unlike Any OtherAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
